Business Wire

IARPA Funds Team Involving DNA Script, the Broad Institute, and Harvard University for DNA Data Storage Research and Development

15.1.2020 20:10:00 EET | Business Wire | Press release

Share

DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to

$23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program. The goal of the project is to develop sequence-controlled polymers as the basis for deployable storage technologies that can eventually scale into the exabyte regime and beyond with reduced physical footprint, power and cost requirements relative to conventional storage technologies.

The Molecular Encoding Consortium is led by the Laboratory of Dr. Robert Nicol at the Broad Institute of MIT and Harvard and includes DNA Script and Professor Donhee Ham’s Research Group at Harvard University. The consortium will explore the possibility of integrating a novel enzymatic DNA synthesis technology and next-generation sequencing into a single instrument over the 4-year duration of the program. The consortium plans to collaborate with Illumina to leverage its sequencing-by-synthesis (SBS) technologies for accurate, low cost decoding.

Massive amounts of digital data are generated every day, and emerging technologies such as autonomous cars and artificial intelligence will further increase the need for data storage at unprecedented scales. This causes major challenges to private and public organizations, which currently rely on exabyte-scale data centers that have large footprints, consume megawatts of power and cost hundreds of millions of dollars to build, operate and maintain over their lifetimes. It is expected that the anticipated growth in data storage requirements cannot be addressed by current resource-intensive technologies. Nucleic acid-based systems hold promise to store this information with radically reduced physical footprints, power and cost requirements.

This technology is not mature yet and will require extensive development to be ready to use. IARPA has therefore launched the MIST program to fund initiatives that could turn molecular-based data storage into reality. The Molecular Encoding Consortium is one of these funded projects.

“This contract with IARPA, which is part of the Office of the Director of National Intelligence, in partnership with prestigious partners such as the Broad Institute and Harvard University is a strong recognition of DNA Script’s results and leadership in developing enzymatic template-free nucleic acid synthesis,” said Dr. Thomas Ybert, CEO of DNA Script. “However, it is only the beginning of this ambitious project, which will require us to push current technological limits to bring to life our cutting-edge technology while also delivering an operational solution to one of the most important challenges of our time.”

“This project at the intersection of molecular biology, physics, chemistry, information theory and electrical engineering leverages the multi-disciplinary capabilities of our laboratory, our exceptional consortium partners and the collaborative nature of our Institute,” said Dr. Robert Nicol, Senior Director of Technology Development at the Broad Institute and the consortium’s Principal Investigator. “The objectives set out by IARPA for this four-year program are ambitious and will require scientific innovations, as well as robust and scalable technologies.”

“The Molecular Encoding Consortium integrates the different experiences and expertise of these leading institutions,” said Dr. Donhee Ham, the Gordon McKay Professor of Electrical Engineering and Applied Physics at Harvard University. “My research group will bring expertise in the interface of solid-state electronic chips and biological systems. I am looking forward to working with the consortium team in combining silicon integrated circuit technology with molecular biology and electrochemistry to tackle this very interesting problem.”

“DNA is the ideal way to store information for long periods of time,” said Dr. Mostafa Ronaghi, Chief Technology Officer of Illumina. “We are excited by the opportunity to collaborate with the early pioneers involved in this project and having our SBS chemistry and instruments used to decode the digital information.”

About IARPA
IARPA invests in high-risk, high-payoff research programs to tackle some of the most difficult challenges of the agencies and disciplines in the Intelligence Community. Additional information on IARPA and its research may be found on www.iarpa.gov.

About DNA Script
Founded in 2014 in Paris, DNA Script is the world’s leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life sciences and technology through rapid, affordable, and high-quality DNA synthesis. DNA Script’s approach leverages nature's billions of years of evolution in synthesizing DNA to enable genome scale synthesis. The Company’s technology has the potential to greatly accelerate the development of new diagnostics, therapeutics, sustainable chemicals production, improved crops and data storage solutions. www.dnascript.co

About the Dr. Donhee Ham Research Group
Established in 2002, one of the major intellectual focuses of Donhee Ham’s research group has been on directly interfacing silicon integrated circuits with biological systems for applications in neuroscience, neurotechnology, and biomolecular spectroscopy. Notably, his group at Harvard Applied Physics in collaboration with Dr. Hongkun Park’s group at Harvard Chemistry has recently developed a silicon electronic chip with a surface nanoelectrode array that can copy the synaptic connectivity of thousands of connected mammalian neurons. http://ham.seas.harvard.edu

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contact in the US for DNA Script
Seismic
Eric Schubert
415-939-4366
eric@teamseismic.com

Press contact in Europe for DNA Script
ALIZE RP
Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

DNA Script Contact
publicrelations@dnascript.com

Illumina Contact
Jen Carroll
jcarroll@illumina.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release

Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release

Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net

RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release

RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye